| Pembrolizumab Monotherapy Following Tri-modality Treatment for Selected Patients With Muscle-invasive Bladder Cancer (NCT05072600) | Peking University First Hospital | 2021-12-07 |
| CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice (NCT02900248) | CureOne | 2017-10-02 |
| Image-Guided Tumorboost of Bladder Cancer (NCT00963404) | University of Aarhus | 2009-08-01 |
| Bladder Cancer Patient-Reported Outcomes (NCT01090388) | Baylor College of Medicine | 2007-07-01 |
| Study of Vicinium for Treating Patients With Non-Invasive Urothelial Carcinoma In Situ (NCT00462488) | Sesen Bio, Inc. | 2007-03-01 |
| Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer (NCT00406068) | Bioniche Life Sciences Inc. | 2006-11-01 |
| A Safety and Tolerability Study of SCH 721015 in Patients With Transitional Cell Carcinoma of the Bladder (Study P03816) (NCT00536588) | Merck Sharp & Dohme LLC | 2006-09-01 |
| Safety and Proof of Concept Study of Intravesical DTA-H19 in Patients With Superficial Bladder Cancer (NCT00393809) | Hebrew University of Jerusalem | 2006-01-01 |
| Phase III Trial of Vinflunine Plus Best Supportive Care vs. Best Supportive Care in Patients With Transitional Cell Carcinoma (TCC) of the Urothelial Tract (NCT00315237) | Pierre Fabre Medicament | 2005-07-01 |
| Phase II Trial of EOquin in High-risk Superficial Bladder Cancer (NCT00141531) | Spectrum Pharmaceuticals, Inc | 2005-07-01 |
| Dose-Escalation Study of CG0070 for Bladder Cancer After BCG (Bacillus Calmette-Guerin) Failure (NCT00109655) | Cell Genesys | 2005-04-01 |
| Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium (NCT00101608) | Bristol-Myers Squibb | 2005-01-01 |
| Combidex USPIO - Ultra-small Superparamagnetic Iron Oxide (NCT00188695) | University Health Network, Toronto | 2004-04-01 |
| Instillation of Gemcitabine in Patients With Superficial Bladder Cancer (NCT00191477) | Eli Lilly and Company | 2004-01-01 |
| TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the Urothelium (NCT00077688) | Achieve Life Sciences | 2003-11-01 |
| Intravesical Chemotherapy Treatment of Superficial Bladder Cancer (NCT00491114) | Eli Lilly and Company | 2003-07-01 |
| Evaluation of Non-Invasive Assays for the Detection of Urothelial Cancer (NCT00872495) | Lahey Clinic | 2002-09-01 |
| Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies (NCT00050687) | Titan Pharmaceuticals | 2001-06-01 |
| Intravesical Epirubicin Plus BCG to Prevent the Recurrence of Transitional Cell Carcinoma of Bladder (NCT00343356) | LanZhou University | 1996-06-01 |
| A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder (NCT00001381) | National Cancer Institute (NCI) | 1994-03-01 |
| Molecular Analysis Of Bladder Cancer (NCT00871754) | Lahey Clinic | 1988-04-01 |